Replication/NN
of/IN
the/DT
Association/NN
between/IN
Copy/NN
Number/NN
Variation/NN
on/IN
8p23.1/NN
and/CC
Autism/NN
by/IN
Using/VBG
ASD-specific/JJ
BAC/NN
Array/NN
./.
====================
Vol/NN
./.
====================
8/CD
(/(
1/LS
)/)
1927/CD
,/,
March/NNP
2010To/RB
discover/RB
genetic/JJ
markers/NNS
for/IN
autism/NN
spectrum/NN
disorder/NN
(/(
ASD/NN
)/)
,/,
we/PRP
previously/RB
applied/VBN
genomewide/NN
BAC/NN
array/NN
comparative/JJ
genomic/JJ
hybridization/NN
(/(
arrayCGH/NN
)/)
to/TO
28/CD
autistic/JJ
patients/NNS
and/CC
62/CD
normal/JJ
controls/NNS
in/IN
Korean/JJ
population/NN
,/,
and/CC
identified/VBD
that/IN
chromosomal/JJ
losses/NNS
on/IN
8p23.1/NN
and/CC
on/IN
17p11.2/CD
are/VBP
significantly/RB
associated/VBN
with/IN
autism/NN
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
developed/VBD
an/DT
8.5K/NN
ASDspecific/JJ
BAC/NN
array/NN
covering/VBG
27/CD
previously/RB
reported/VBN
ASDassociated/JJ
CNV/NN
loci/NNS
including/VBG
ours/VBZ
and/CC
examined/VBD
whether/IN
the/DT
associations/NNS
would/MD
be/VB
replicated/VBN
in/IN
8/CD
ASD/NN
patient/NN
cell/NN
lines/NNS
of/IN
four/CD
different/JJ
ethnic/JJ
groups/NNS
and/CC
10/CD
Korean/JJ
normal/JJ
controls/NNS
./.
====================
As/IN
a/DT
result/NN
,/,
a/DT
CNV-loss/NN
on/IN
8p23.1/NN
was/VBD
found/VBN
to/TO
be/VB
significantly/RB
more/RBR
frequent/JJ
in/IN
patients/NNS
regardless/RB
of/IN
ethnicity/NN
(/(
p＜0.0001/CD
)/)
./.
====================
This/DT
CNV/NN
region/NN
contains/VBZ
two/CD
coding/VBG
genes/NNS
,/,
DEFA1/NN
and/CC
DEFA3/NN
,/,
which/WDT
are/VBP
members/NNS
of/IN
DEFENSIN/NN
gene/NN
family/NN
./.
====================
Two/CD
other/JJ
CNVs/NNS
on/IN
17p11.2/CD
and/CC
Xp22.31/NN
were/VBD
also/RB
distributed/VBN
differently/RB
between/IN
ASDs/NNS
and/CC
controls/VBZ
,/,
but/CC
not/RB
significant/JJ
(/(
p=0.069/CD
and/CC
0.092/CD
,/,
respectively/RB
)/)
./.
====================
All/DT
the/DT
other/JJ
loci/NNS
did/VBD
not/RB
show/VB
significant/JJ
association/NN
./.
====================
When/WRB
these/DT
evidences/NNS
are/VBP
considered/VBN
,/,
the/DT
association/NN
between/IN
ASD/NN
and/CC
CNV/NN
of/IN
DEFENSIN/NN
gene/NN
seems/VBZ
worthy/NN
of/IN
further/JJ
exploration/NN
to/TO
elucidate/VB
the/DT
pathogenesis/NN
of/IN
ASD/NN
./.
====================
Validation/NN
studies/NNS
with/IN
a/DT
larger/JJR
sample/NN
size/NN
will/MD
be/VB
required/VBN
to/TO
verify/VB
its/PRP$
biological/JJ
implication/NN
./.
====================
Autism/NN
spectrum/NN
disorder/NN
(/(
ASD/NN
)/)
is/VBZ
neurodevelopmental/JJ
syndrome/NN
with/IN
a/DT
broad/JJ
spectrum/NN
of/IN
phenotypes/NNS
including/VBG
profound/JJ
deficits/NNS
in/IN
social/JJ
relatedness/NN
and/CC
communication/NN
,/,
repetitive/JJ
behaviors/NNS
,/,
and/CC
restricted/JJ
interests/NNS
(/(
Rutter/NN
,/,
2005/CD
)/)
./.
====================
There/EX
is/VBZ
accumulating/VBG
evidence/NN
which/WDT
suggests/VBZ
substantial/JJ
genetic/JJ
contribution/NN
to/TO
ASD/NN
development/NN
(/(
Folstein/NN
and/CC
RosenSheidley/NNP
,/,
2001/CD
;/:
Veenstra/NNP
VanderWeele/NN
and/CC
Cook/JJ
,/,
2004/CD
)/)
./.
====================
For/IN
example/NN
,/,
the/DT
concordance/NN
rate/NN
of/IN
autism/NN
was/VBD
significantly/RB
higher/JJR
in/IN
monozygotic/JJ
twins/NNS
than/IN
in/IN
dizygotic/JJ
twins/NNS
(/(
Folstein/NN
and/CC
RosenSheidley/NNP
,/,
2001/CD
;/:
VeenstraVanderWeele/NNP
and/CC
Cook/JJ
,/,
2004/CD
)/)
./.
====================
Although/IN
previous/JJ
studies/NNS
including/VBG
linkage/NN
analyses/NNS
have/VBP
revealed/VBN
a/DT
number/NN
of/IN
potential/JJ
ASDassociated/JJ
loci/NNS
,/,
genetic/JJ
and/CC
phenotypic/JJ
heterogeneity/NN
of/IN
the/DT
disease/NN
has/VBZ
made/VBN
it/PRP
difficult/JJ
to/TO
replicate/VB
the/DT
results/NNS
as/IN
well/RB
as/IN
to/TO
identify/VB
ASDassociated/JJ
genetic/JJ
mechanisms/NNS
(/(
Folstein/NN
and/CC
RosenSheidley/NNP
,/,
2001/CD
;/:
Klauck/NN
,/,
2006/CD
;/:
VeenstraVanderWeele/NNP
and/CC
Cook/JJ
,/,
2004/CD
)/)
./.
====================
Recently/RB
a/DT
new/JJ
type/NN
of/IN
human/JJ
genetic/JJ
variation/NN
named/VBD
copy/NN
number/NN
variant/JJ
(/(
CNV/NN
)/)
has/VBZ
been/VBN
suggested/VBN
as/IN
one/CD
of/IN
the/DT
major/JJ
sources/NNS
of/IN
genomic/JJ
diversity/NN
ranging/VBG
from/IN
normal/JJ
phenotypic/JJ
heterogeneity/NN
to/TO
disease/NN
susceptibility/NN
(/(
Freeman/JJ
et/FW
al./FW
,/,
2006/CD
;/:
Iafrate/NNP
et/FW
al./FW
,/,
2004/CD
;/:
Sebat/NNP
et/FW
al./FW
,/,
2004/CD
)/)
./.
====================
Indeed/RB
,/,
lines/NNS
of/IN
evidence/NN
have/VBP
been/VBN
reported/VBN
which/WDT
demonstrated/VBD
the/DT
association/NN
between/IN
CNV/NN
and/CC
ASD/NN
(/(
Cho/NNP
et/FW
al./FW
,/,
2009/CD
;/:
Cook/NNP
and/CC
Scherer/NNP
,/,
2008/CD
;/:
Glessner/NN
et/FW
al./FW
,/,
2009/CD
;/:
Marshall/NNP
et/FW
al./FW
,/,
2008/CD
;/:
Sebat/NNP
et/FW
al./FW
,/,
2007/CD
)/)
./.
====================
In/IN
our/PRP$
previous/JJ
study/NN
,/,
we/PRP
identified/VBD
38/CD
copy/NN
number/NN
variable/JJ
regions/NNS
in/IN
ASD/NN
patients/NNS
,/,
two/CD
of/IN
which/WDT
(/(
CNVs/NNS
on/IN
8p23.1/NN
and/CC
17p11.2/CD
)/)
were/VBD
found/VBN
to/TO
be/VB
significantly/RB
associated/VBN
with/IN
ASD/NN
(/(
Cho/NNP
et/FW
al./FW
,/,
2009/CD
)/)
./.
====================
Using/VBG
27/CD
CNV/NN
loci/NNS
previously/RB
reported/VBD
to/TO
be/VB
associated/VBN
with/IN
ASD/NN
including/VBG
ours/VBZ
,/,
we/PRP
developed/VBD
an/DT
8.5K/NN
ASDspecific/JJ
BAC/NN
array/NN
and/CC
screened/VBN
whether/IN
the/DT
association/NN
between/IN
those/DT
CNVs/NNS
would/MD
be/VB
replicated/VBN
in/IN
patient/NN
cell/NN
lines/NNS
of/IN
four/CD
different/JJ
ethnic/JJ
groups/NNS
./.
====================
We/PRP
used/VBD
DNA/NN
extracted/VBN
from/IN
Blymphocyte/NN
cell/NN
lines/NNS
of/IN
8/CD
ASD/NN
patients/NNS
of/IN
four/CD
different/JJ
ethnicities/NNS
;/:
Caucasian/JJ
,/,
Chinese/JJ
,/,
Asiatic/JJ
Indian/JJ
,/,
and/CC
Hispanic/JJ
(/(
Coriell/NN
Institute/JJ
for/IN
Medical/JJ
Research/NN
,/,
Camden/JJ
,/,
NJ/NNP
,/,
USA/NNP
)/)
./.
====================
General/JJ
characteristics/NNS
of/IN
the/DT
8/CD
ASD/NN
patients/NNS
are/VBP
shown/VBN
in/IN
Table/JJ
1/CD
./.
====================
As/IN
normal/JJ
control/JJ
subjects/NNS
,/,
we/PRP
used/VBD
10/CD
normal/JJ
Korean/JJ
adults/NNS
without/IN
any/DT
sign/JJ
of/IN
ASD/NN
and/CC
other/JJ
genetic/JJ
disorders/NNS
./.
====================
Using/VBG
the/DT
D5500A/NN
PUREGENE/NN
DNA/NN
Isolation/NN
kit/NN
(/(
QIAGEN/NN
,/,
Valencia/NN
,/,
CA/NNP
,/,
USA/NNP
)/)
,/,
we/PRP
extracted/VBD
genomic/JJ
DNA/NN
from/IN
the/DT
blood/NN
of/IN
controls/NNS
according/VBG
to/TO
manufacturer/VB
’/CD
s/NNS
instructions/NNS
./.
====================
DNA/NN
quantity/NN
and/CC
quality/NN
were/VBD
checked/VBN
by/IN
a/DT
NanoDrop/JJ
assay/NN
and/CC
1/CD
%/NN
agarose/NN
gel/NN
electrophoresis/NN
./.
====================
This/DT
study/NN
was/VBD
performed/VBN
under/IN
the/DT
approval/JJ
of/IN
the/DT
Institutional/JJ
Review/NN
Boards/NNS
of/IN
The/DT
Catholic/JJ
University/NN
of/IN
Korea/NN
(/(
CUMC07U025/NN
)/)
./.
====================
In/IN
total/JJ
,/,
846/CD
BAC/NN
clones/NNS
representing/VBG
the/DT
27/CD
candidate/NN
CNV/NN
regions/NNS
were/VBD
selected/VBN
from/IN
the/DT
DNA/NN
BAC/NN
library/NN
(/(
Macrogen/NN
,/,
Seoul/JJ
,/,
Korea/NN
)/)
and/CC
the/DT
BAC/NN
clone/NN
DNA/NN
was/VBD
extracted/VBN
as/IN
described/VBN
elsewhere/RB
(/(
Cho/NNP
et/FW
al./FW
,/,
2009/CD
;/:
Chung/JJ
et/FW
al./FW
,/,
2004/CD
)/)
./.
====================
In/IN
brief/JJ
,/,
each/DT
BAC/NN
clone/NN
was/VBD
isolated/VBN
,/,
grown/VBN
in/IN
500ml/JJ
of/IN
culture/NN
media/NNS
,/,
pelleted/JJ
,/,
from/IN
which/WDT
DNA/NN
was/VBD
extracted/VBN
using/VBG
an/DT
alkaline/NN
lysis/NN
method/NN
./.
====================
All/DT
selected/VBN
clones/NNS
were/VBD
bi-directionally/RB
sequenced/VBN
using/VBG
the/DT
ABI/NN
PRISM/NN
3700/CD
DNA/NN
Analyzer/NN
(/(
Applied/VBN
Biosystems/NNS
,/,
Foster/NN
City/NN
,/,
CA/NNP
,/,
USA/NNP
)/)
,/,
and/CC
their/PRP$
sequences/NNS
were/VBD
blasted/VBN
and/CC
mapped/VBD
according/VBG
to/TO
their/PRP$
linear/JJ
positions/NNS
./.
====================
Extracted/JJ
BAC/NN
DNA/NN
was/VBD
dissolved/VBN
in/IN
50/CD
%/NN
DMSO/NN
with/IN
a/DT
concentration/NN
of/IN
400~500ng/ul/JJ
and/CC
spotted/JJ
in/IN
triplicate/NN
onto/IN
the/DT
glass/NN
by/IN
the/DT
Genemachines/NNS
OmniGrid/JJ
100/CD
arrayer/NN
(/(
Digilab/NN
Genomic/JJ
Solutions/NNS
,/,
Holliston/NNP
,/,
MA/NN
,/,
USA/NNP
)/)
./.
====================
We/PRP
used/VBD
Corning/JJ
UltraGAPS/NN
amine/NN
coating/VBG
slides/NNS
(/(
Corning/NN
,/,
Acton/NNP
,/,
MA/NN
,/,
USA/NNP
)/)
and/CC
Telecam/JJ
SMP4/NN
pins/VBZ
(/(
Arrayit/NN
Corporation/NN
,/,
Sunnyvale/JJ
,/,
CA/NNP
,/,
USA/NNP
)/)
for/IN
DNA/NN
spotting/NN
./.
====================
We/PRP
followed/VBD
processes/NNS
for/IN
a/DT
general/JJ
contact/NN
type/NN
spotter/CD
./.
====================
Array-CGH/NN
was/VBD
performed/VBN
as/IN
described/VBN
elsewhere/RB
using/VBG
the/DT
MAUI/NN
hybridization/NN
station/NN
(/(
BioMicro/NNP
Systems/NNS
,/,
Salt/NN
Lake/NN
City/NN
,/,
Utah/NNP
,/,
USA/NNP
)/)
(/(
Joo/NNP
et/FW
al./FW
,/,
2008/CD
)/)
./.
====================
In/IN
one/CD
tube/NN
,/,
Cy3labeled/JJ
sample/JJ
and/CC
Cy5labeled/JJ
reference/VBP
DNAs/NNS
were/VBD
mixed/VBN
together/RB
and/CC
50μg/JJ
human/JJ
Cot/NN
I/NN
DNA/NN
(/(
HybMasker/NN
,/,
ConnectaGen/NN
,/,
Seoul/JJ
,/,
Korea/NN
)/)
,/,
20μl/JJ
of/IN
3/CD
M/NN
sodium/NN
acetate/NN
and/CC
600μl/JJ
of/IN
cold/JJ
100/CD
%/NN
ethanol/NN
were/VBD
added/VBN
to/TO
precipitate/VB
DNA/NN
./.
====================
The/DT
obtained/VBN
pellet/NN
was/VBD
resuspended/VBN
in/IN
40μl/JJ
of/IN
hybridization/NN
solution/NN
containing/VBG
50/CD
%/NN
formamide/IN
,/,
10/CD
%/NN
dextran/NN
sulfate/NN
,/,
2/CD
SSC/NN
,/,
4/CD
%/NN
SDS/NN
and/CC
200/CD
ug/NN
of/IN
yeast/NN
tRNA/NN
./.
====================
Hybridization/NN
was/VBD
performed/VBN
in/IN
slide/JJ
chambers/NNS
for/IN
48/CD
hr/NN
at/IN
37C/NN
./.
====================
After/IN
the/DT
hybridization/NN
,/,
slides/NNS
were/VBD
washed/VBN
serially/RB
at/IN
room/JJ
temperature/NN
in/IN
solution/NN
1/CD
(/(
2X/CD
salinesodium/NN
citrate/JJ
(/(
SSC/NN
)/)
,/,
0.1/CD
%/NN
SDS/NN
)/)
for/IN
10/CD
min/NN
(/(
1X/CD
)/)
,/,
in/IN
solution/NN
2/CD
(/(
0.1X/CD
SSC/NN
,/,
0.1/CD
%/NN
SDS/NN
)/)
for/IN
10/CD
min/NN
(/(
2X/CD
)/)
and/CC
in/IN
solution/NN
3/CD
(/(
0.1X/CD
SSC/NN
)/)
for/IN
1/CD
min/NN
(/(
3X/NN
)/)
followed/VBN
by/IN
rinsing/VBG
in/IN
distilled/JJ
water/RB
for/IN
10/CD
sec/JJ
./.
====================
Finally/RB
,/,
the/DT
slides/NNS
were/VBD
spindried/VBN
for/IN
2/CD
min/NN
at/IN
1000/CD
rpm/NN
./.
====================
All/DT
the/DT
experiments/NNS
were/VBD
duplicated/VBN
and/CC
dye/NN
swapping/VBG
was/VBD
done/VBN
for/IN
more/RBR
reliable/JJ
interpretation/NN
./.
====================
Arrays/NNS
were/VBD
scanned/VBN
and/CC
analyzed/VBD
using/VBG
the/DT
GenePix/NN
4200A/NN
twocolor/JJ
fluorescent/JJ
scanner/NN
(/(
MDS/NN
Analytical/JJ
Technologies/NNS
,/,
Sunnyvale/JJ
,/,
CA/NNP
,/,
USA/NNP
)/)
and/CC
the/DT
images/NNS
were/VBD
processed/VBN
using/VBG
the/DT
MacViewer/NN
1.6/CD
imaging/NN
software/RB
(/(
Macrogen/NN
,/,
Seoul/JJ
,/,
Korea/NN
)/)
./.
====================
Signal/NN
intensity/NN
ratios/NNS
(/(
test/reference/NN
)/)
were/VBD
measured/VBN
and/CC
converted/VBD
to/TO
log2/NN
scale/NN
./.
====================
Background/JJ
corrected/VBD
signal/NN
intensity/NN
ratios/NNS
were/VBD
normalized/VBN
using/VBG
Lowess/JJ
normalization/NN
./.
====================
For/IN
defining/VBG
CNVs/NNS
,/,
we/PRP
set/VBP
the/DT
cutoff/JJ
values/NNS
of/IN
signal/JJ
intensity/NN
ratios/NNS
at/IN
above/JJ
0.25/CD
(/(
log2/NN
scale/JJ
)/)
for/IN
copy/NN
number/NN
gain/NN
and/CC
at/IN
below/IN
−0.25/CD
for/IN
copy/NN
number/NN
loss/NN
according/VBG
to/TO
our/PRP$
previous/JJ
study/NN
(/(
Cho/NNP
et/FW
al./FW
,/,
2009/CD
;/:
Jeong/NNP
et/FW
al./FW
,/,
2008/CD
)/)
./.
====================
We/PRP
also/RB
analyzed/VBD
dyeswap/NN
experiment/NN
results/NNS
to/TO
get/VB
more/RBR
reliable/JJ
CNV/NN
call/JJ
./.
====================
If/IN
a/DT
CNV/NN
call/JJ
is/VBZ
true/JJ
,/,
its/PRP$
test/reference/NN
intensity/NN
ratio/NN
value/NN
must/MD
be/VB
inverted/VBN
by/IN
switching/NN
the/DT
dyes/NNS
./.
====================
Only/RB
the/DT
original/JJ
ratios/NNS
and/CC
inverted/VBD
dye/NN
swap/NN
signals/NNS
were/VBD
observed/VBN
,/,
the/DT
according/VBG
CNV/NN
was/VBD
called/VBN
as/IN
a/DT
true/JJ
one/CD
./.
====================
We/PRP
used/VBD
Stata/NN
version/NN
10.0/CD
(/(
Stata/NNS
Corporation/NN
,/,
College/NN
Station/NN
,/,
Tx/NNP
)/)
and/CC
performed/VBN
the/DT
chi-square/NN
or/CC
Fisher/RB
’/CD
s/NNS
exact/JJ
test/NN
to/TO
compare/VB
the/DT
distribution/NN
of/IN
CNV/NN
regions/NNS
between/IN
cases/NNS
and/CC
controls/VBZ
./.
====================
False/NN
discovery/NN
rate/NN
(/(
FDR/NN
)/)
was/VBD
used/VBN
for/IN
multiple/JJ
comparisons/NNS
correction/NN
./.
====================
p/NN
values/NNS
less/RBR
than/IN
0.05/CD
was/VBD
considered/VBN
statistically/RB
significant/JJ
./.
====================
We/PRP
developed/VBD
a/DT
ASD-specific/JJ
BAC/NN
array/NN
named/VBN
‘/NN
MacArray/NN
Karyo/JJ
Autism/NN
Prototype/JJ
’/NNP
which/WDT
covers/VBZ
a/DT
total/JJ
of/IN
27/CD
CNV/NN
regions/NNS
that/IN
have/VBP
been/VBN
reported/VBN
to/TO
be/VB
associated/VBN
with/IN
autism/NN
in/IN
previous/JJ
studies/NNS
including/VBG
ours/VBZ
(/(
Cho/NNP
et/FW
al./FW
,/,
2009/CD
;/:
Klauck/NNP
,/,
2006/CD
;/:
Schellenberg/NNP
et/FW
al./FW
,/,
2006/CD
;/:
Sultana/NNP
et/FW
al./FW
,/,
2002/CD
;/:
Vorstman/NNP
et/FW
al./FW
,/,
2006/CD
)/)
./.
====================
A/DT
total/JJ
of/IN
846/CD
BAC/NN
clones/NNS
representing/VBG
the/DT
candidate/NN
27/CD
CNV/NN
regions/NNS
were/VBD
selected/VBN
for/IN
designing/VBG
ASDspecific/JJ
BAC/NN
array/NN
(/(
Fig/NN
./.
====================
1/CD
)/)
./.
====================
Locus/FW
specificities/NNS
of/IN
selected/VBN
clones/NNS
were/VBD
improved/VBN
by/IN
removing/VBG
multiple/JJ
locibinding/VBG
clones/NNS
under/IN
standard/JJ
fluorescence/NN
in/FW
situ/FW
hybridization/NN
(/(
FISH/NN
)/)
./.
====================
The/DT
information/NN
about/IN
those/DT
targeted/VBN
27/CD
genomic/JJ
regions/NNS
and/CC
846/CD
BAC/NN
clones/NNS
is/VBZ
available/JJ
in/IN
Supplementary/JJ
data/NNS
1/CD
./.
====================
Among/IN
the/DT
846/CD
BAC/NN
clones/NNS
,/,
77/CD
spots/NNS
(/(
15/CD
loci/NNS
)/)
showed/VBD
CNVs/NNS
in/IN
at/IN
least/JJS
2/CD
study/NN
participants/NNS
./.
====================
Details/NNS
of/IN
the/DT
CNV/NN
profiles/NNS
of/IN
the/DT
8/CD
ASDs/NNS
and/CC
10/CD
normal/JJ
controls/NNS
for/IN
the/DT
77/CD
spots/NNS
are/VBP
available/JJ
in/IN
supplementary/JJ
data/NNS
2/CD
./.
====================
Of/IN
the/DT
77/CD
spots/NNS
,/,
a/DT
CNVloss/NN
on/IN
8p23.1/NN
(/(
BAC168_A06/NN
)/)
was/VBD
found/VBN
to/TO
be/VB
significantly/RB
more/RBR
frequent/JJ
in/IN
ASD/NN
patients/NNS
(/(
7/CD
out/IN
of/IN
8/CD
ASD/NN
patients/NNS
versus/CC
none/NN
in/IN
controls/NNS
,/,
p＜/RB
0.0001/CD
)/)
(/(
Table/JJ
2/CD
)/)
./.
====================
Two/CD
other/JJ
CNVs/NNS
were/VBD
distributed/VBN
differently/RB
between/IN
patients/NNS
and/CC
controls/VBZ
,/,
but/CC
not/RB
significant/JJ
./.
====================
A/DT
CNVloss/NN
on/IN
17p11.2/CD
(/(
BAC130_G23/NN
)/)
was/VBD
found/VBN
in/IN
3/CD
out/RP
of/IN
8/CD
ASD/NN
patients/NNS
,/,
but/CC
not/RB
in/IN
controls/NNS
(/(
p=0.069/CD
)/)
./.
====================
A/DT
CNVgain/NN
on/IN
Xp22.31/NN
(/(
BAC231_F19/NN
)/)
was/VBD
found/VBN
in/IN
4/CD
out/RB
of/IN
10/CD
controls/NNS
,/,
but/CC
not/RB
in/IN
ASDs/NNS
(/(
p=0.092/NN
)/)
(/(
Table/JJ
2/CD
)/)
./.
====================
The/DT
most/JJS
significant/JJ
CNV/NN
region/NN
(/(
BAC168_A06/NN
,/,
8p23.1/NN
)/)
contains/VBZ
two/CD
coding/VBG
genes/NNS
,/,
DEFA1/NN
and/CC
DEFA3/NN
,/,
which/WDT
are/VBP
members/NNS
of/IN
DEFENSIN/NN
gene/NN
family/NN
./.
====================
Interestingly/RB
,/,
the/DT
copy/NN
number/NN
loss/NN
CNV/NN
on/IN
8p23.1/NN
was/VBD
identified/VBN
in/IN
all/DT
four/CD
different/JJ
ethnic/JJ
groups/NNS
and/CC
also/RB
consistent/JJ
in/IN
duplicated/JJ
experiments/NNS
./.
====================
Fig/NN
./.
====================
2/CD
shows/VBZ
the/DT
examples/NNS
of/IN
CNVs/NNS
on/IN
8p23.1/NN
and/CC
17p11.2/CD
in/IN
ASD/NN
patients/NNS
,/,
which/WDT
are/VBP
duplicated/VBN
and/CC
dye/NN
swapped/VBD
and/CC
no/DT
CNVs/NNS
in/IN
normal/JJ
control/JJ
individuals/NNS
./.
====================
It/PRP
has/VBZ
been/VBN
widely/RB
accepted/VBN
that/IN
ASD/NN
has/VBZ
a/DT
strong/JJ
genetic/JJ
background/NN
(/(
Folstein/NN
and/CC
Rosen-Sheidley/NNP
,/,
2001/CD
;/:
Rutter/NN
,/,
2005/CD
;/:
Veenstra-VanderWeele/NNP
and/CC
Cook/JJ
,/,
2004/CD
)/)
./.
====================
Although/IN
genomic/JJ
loci/NNS
or/CC
genes/NNS
reported/VBN
to/TO
be/VB
associated/VBN
with/IN
ASD/NN
were/VBD
not/RB
easily/RB
replicated/VBN
in/IN
subsequent/JJ
studies/NNS
for/IN
many/JJ
reasons/NNS
such/JJ
as/IN
disease/NN
heterogeneity/NN
per/IN
se/FW
and/CC
relatively/RB
high/JJ
noise/RB
levels/NNS
of/IN
genomics/NNS
technology/NN
used/VBN
,/,
some/DT
of/IN
the/DT
ASDassociated/JJ
CNVs/NNS
have/VBP
been/VBN
successfully/RB
replicated/VBN
./.
====================
For/IN
example/NN
,/,
CNVs/NNS
in/IN
NRXN1/NN
,/,
NLGN4/NN
and/CC
SHANK3/NN
genes/NNS
,/,
which/WDT
had/VBD
been/VBN
identified/VBN
in/IN
target/NN
gene/NN
studies/NNS
,/,
were/VBD
replicated/VBN
in/IN
genomewide/NN
CNV/NN
studies/NNS
for/IN
ASD/NN
(/(
Glessner/NN
et/FW
al./FW
,/,
2009/CD
;/:
Marshall/NNP
et/FW
al./FW
,/,
2008/CD
)/)
./.
====================
Given/IN
that/DT
SNPs/NNS
or/CC
other/JJ
genetic/JJ
markers/NNS
were/VBD
not/RB
very/RB
consistent/JJ
in/IN
ASD/NN
,/,
this/DT
suggests/VBZ
that/IN
structural/JJ
variation/NN
could/MD
be/VB
a/DT
more/RBR
consistent/JJ
and/CC
important/JJ
marker/NN
in/IN
ASD/NN
and/CC
facilitate/VBP
the/DT
elucidation/NN
of/IN
genetic/JJ
mechanisms/NNS
behind/VBP
the/DT
disease/NN
./.
====================
In/IN
our/PRP$
previous/JJ
study/NN
,/,
we/PRP
identified/VBD
38/CD
CNV/NN
regions/NNS
in/IN
28/CD
Korean/NN
ASD/NN
patients/NNS
and/CC
two/CD
of/IN
them/PRP
(/(
CNVs/NNS
on/IN
8p23.1/NN
and/CC
17p11.2/CD
)/)
were/VBD
significantly/RB
associated/VBN
with/IN
ASD/NN
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
designed/VBD
and/CC
prepared/VBN
an/DT
ASDspecific/JJ
BAC/NN
array/NN
for/IN
CNV/NN
analysis/NN
and/CC
examined/VBN
whether/IN
the/DT
significant/JJ
CNV/NN
markers/NNS
would/MD
be/VB
replicated/VBN
in/IN
independent/JJ
ASD/NN
patients/NNS
of/IN
diverse/JJ
ethnic/JJ
origins/NNS
./.
====================
The/DT
ASD-specific/JJ
BAC/NN
array/NN
contains/VBZ
the/DT
two/CD
significant/JJ
CNV/NN
regions/NNS
identified/VBD
in/IN
our/PRP$
previous/JJ
study/NN
and/CC
also/RB
25/CD
putative/JJ
ASD-associated/JJ
regions/NNS
reported/VBD
by/IN
previous/JJ
linkage/NN
studies/NNS
(/(
Cho/NNP
et/FW
al./FW
,/,
2009/CD
;/:
Klauck/NNP
,/,
2006/CD
;/:
Rutter/NNP
,/,
2005/CD
;/:
Schellenberg/NNP
et/FW
al./FW
,/,
2006/CD
;/:
Sultana/NNP
et/FW
al./FW
,/,
2002/CD
;/:
Vorstman/NNP
et/FW
al./FW
,/,
2006/CD
)/)
./.
====================
However/RB
,/,
all/DT
25/CD
candidate/NN
regions/NNS
suggested/VBD
by/IN
linkage/NN
analyses/NNS
were/VBD
not/RB
replicated/VBN
in/IN
our/PRP$
study/NN
population/NN
./.
====================
This/DT
data/NNS
seems/VBZ
coherent/JJ
with/IN
previous/JJ
observations/NNS
that/IN
positive/JJ
findings/NNS
from/IN
one/CD
linkage/NN
study/NN
often/RB
fail/VBP
to/TO
replicate/VB
in/IN
the/DT
other/JJ
observation/NN
(/(
Glessner/NN
et/FW
al./FW
,/,
2009/CD
)/)
,/,
but/CC
it/PRP
could/MD
be/VB
due/JJ
to/TO
small/JJ
sample/NN
size/NN
of/IN
the/DT
study/NN
./.
====================
In/IN
this/DT
study/NN
,/,
the/DT
association/NN
of/IN
copy/NN
number/NN
loss/NN
CNV/NN
on/IN
8p23.1/NN
with/IN
ASD/NN
was/VBD
consistently/RB
replicated/VBN
in/IN
diverse/JJ
ethnic/JJ
groups/NNS
./.
====================
8p23.1/CD
locus/NN
is/VBZ
known/VBN
to/TO
be/VB
a/DT
frequent/JJ
region/NN
of/IN
DNA/NN
structural/JJ
variation/NN
in/IN
human/JJ
(/(
Hollox/NN
et/FW
al./FW
,/,
2008a/NN
)/)
./.
====================
DEFENSIN/NN
gene/NN
family/NN
,/,
which/WDT
is/VBZ
a/DT
well-known/JJ
component/NN
of/IN
innate/JJ
immunity/NN
,/,
is/VBZ
clustered/VBN
in/IN
this/DT
region/NN
(/(
Ganz/NNP
,/,
1999/CD
;/:
Hollox/NN
et/FW
al./FW
,/,
2008a/CD
)/)
./.
====================
CNV/NN
of/IN
DEFENSIN/NN
family/NN
,/,
especially/RB
betadefensin/IN
,/,
has/VBZ
been/VBN
reported/VBN
as/IN
a/DT
risk/NN
factor/NN
for/IN
different/JJ
diseases/NNS
such/JJ
as/IN
psoriasis/NN
,/,
Crohn/NN
’/CD
s/NNS
disease/NN
and/CC
cystic/JJ
fibrosis/NN
(/(
Hollox/NN
,/,
2008b/NNP
;/:
Hollox/NNP
et/FW
al./FW
,/,
2008c/JJ
)/)
,/,
which/WDT
suggests/VBZ
that/IN
CNV/NN
of/IN
DEFENSIN/NN
family/NN
is/VBZ
likely/RB
to/TO
be/VB
associated/VBN
with/IN
autoimmune/JJ
diseases/NNS
./.
====================
Immunological/JJ
dysfunction/NN
has/VBZ
been/VBN
suggested/VBN
to/TO
be/VB
associated/VBN
with/IN
autism/NN
(/(
Folstein/NN
and/CC
Rosen-Sheidley/NNP
,/,
2001/CD
;/:
Rutter/NNP
,/,
2005/CD
)/)
and/CC
the/DT
copy/NN
number/NN
loss/NN
on/IN
8p23.1/NN
was/VBD
reported/VBN
to/TO
be/VB
associated/VBN
with/IN
behavioral/JJ
problems/VBZ
or/CC
mental/JJ
slowness/JJ
(/(
Pettenati/NNP
et/FW
al./FW
,/,
1992/CD
)/)
./.
====================
When/WRB
this/DT
evidence/NN
is/VBZ
considered/VBN
,/,
the/DT
association/NN
between/IN
ASD/NN
and/CC
CNV/NN
of/IN
DEFENSIN/NN
gene/NN
seems/VBZ
worthy/NN
of/IN
further/JJ
exploration/NN
to/TO
elucidate/VB
the/DT
pathogenesis/NN
of/IN
ASD/NN
./.
====================
Validation/NN
studies/NNS
with/IN
a/DT
larger/JJR
sample/NN
size/NN
will/MD
be/VB
required/VBN
to/TO
verify/VB
its/PRP$
biological/JJ
implication/NN
./.
====================
